

Special Issue

Novel Strategies for Enhancing the Therapeutic Effect of Bioactive Compounds in the Treatment of Rheumatic Diseases

Message from the Guest Editor

A special interest in the field of nanomedicine is the development of the innovative and efficient nanocarriers with controllable properties for drug delivery and site-specific targeting able to achieve greater efficacy and minimize the toxic effects associated with conventional therapies. The therapeutic profiles of biological and pharmacological agents can be improved by incorporation into nanocarrier systems. In the case of rheumatic diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA), nanoparticles containing bioactive compounds can offer tremendous opportunities in diagnosis, monitoring, and treatment.

This Special Issue will highlight novel strategies exploring the potential of nanocarriers-based bioproducts of natural origin (included but not limited to vegetal and animal sources), with a focus on rheumatic diseases. Data regarding the design, physico-chemical properties, biocompatibility, anti-inflammatory, and regenerative potential of the pharmaceutical nanoformulations are encouraged. Their performance in vitro and in vivo—especially for local/intra-articular applications (but not limited to these)—and clinical assays are welcome.

Guest Editor

Dr. Mihaela Trif

Institute of Biochemistry, Romanian Academy, Bucharest, Romania

Deadline for manuscript submissions

closed (10 May 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/72276

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).